Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Schott

Showing results (41-50 of 69) with videos related to

Pageof 7
Sort By:
Breast Cancer Research and Treatment|August 1, 2016
Phase II studies of two different schedules of dasatinib in bone metastasis predominant metastatic breast cancer: SWOG S0622Anne F Schott, William E Barlow, Catherine H Van Poznak, et al.
Pharmacogenomics|December 7, 2018
Patients carrying CYP2C8*3 have shorter systemic paclitaxel exposureLauren A Marcath, Kelley M Kidwell, Adam C Robinson, et al.
Breast Cancer Research and Treatment|July 8, 2021
Improving the delivery of team-based survivorship care after primary breast cancer treatment through a multi-level intervention: a pilot randomized controlled trialLauren P Wallner, Paul Abrahamse, Joan G Gargaro, et al.
Annals of Surgical Oncology|September 12, 2008
Axillary staging prior to neoadjuvant chemotherapy for breast cancer: predictors of recurrenceKandice E Kilbride, M Catherine Lee, Alexis V Nees, et al.
The Oncologist|January 24, 2012
Phase II trial of simple oral therapy with capecitabine and cyclophosphamide in patients with metastatic breast cancer: SWOG S0430Anne F Schott, William E Barlow, Kathy S Albain, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 29, 2018
Paclitaxel Plasma Concentration after the First Infusion Predicts Treatment-Limiting Peripheral NeuropathyDaniel L Hertz, Kelley M Kidwell, Kiran Vangipuram, et al.
Breast Cancer Research and Treatment|September 3, 2021
A randomized, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for metastatic triple-negative breast cancer (fRida)Lori J Goldstein, Mauro Mansutti, Christelle Levy, et al.
Breast Cancer Research and Treatment|September 13, 2005
Clinical and radiologic assessments to predict breast cancer pathologic complete response to neoadjuvant chemotherapyAnne F Schott, Marilyn A Roubidoux, Mark A Helvie, et al.
Translational Oncology|April 29, 2014
Image registration for quantitative parametric response mapping of cancer treatment responseJennifer L Boes, Benjamin A Hoff, Nola Hylton, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|September 29, 2009
Fever and neutropenia clinical practice guidelinesAlison G Freifeld, Lindsey Robert Baden, Arthur E Brown, et al.
Pageof 7

Showing results (41-50 of 69) with videos related to

Sort By:
Pageof 7
Breast Cancer Research and Treatment|August 1, 2016
Phase II studies of two different schedules of dasatinib in bone metastasis predominant metastatic breast cancer: SWOG S0622Anne F Schott, William E Barlow, Catherine H Van Poznak, et al.
Pharmacogenomics|December 7, 2018
Patients carrying CYP2C8*3 have shorter systemic paclitaxel exposureLauren A Marcath, Kelley M Kidwell, Adam C Robinson, et al.
Breast Cancer Research and Treatment|July 8, 2021
Improving the delivery of team-based survivorship care after primary breast cancer treatment through a multi-level intervention: a pilot randomized controlled trialLauren P Wallner, Paul Abrahamse, Joan G Gargaro, et al.
Annals of Surgical Oncology|September 12, 2008
Axillary staging prior to neoadjuvant chemotherapy for breast cancer: predictors of recurrenceKandice E Kilbride, M Catherine Lee, Alexis V Nees, et al.
The Oncologist|January 24, 2012
Phase II trial of simple oral therapy with capecitabine and cyclophosphamide in patients with metastatic breast cancer: SWOG S0430Anne F Schott, William E Barlow, Kathy S Albain, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 29, 2018
Paclitaxel Plasma Concentration after the First Infusion Predicts Treatment-Limiting Peripheral NeuropathyDaniel L Hertz, Kelley M Kidwell, Kiran Vangipuram, et al.
Breast Cancer Research and Treatment|September 3, 2021
A randomized, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for metastatic triple-negative breast cancer (fRida)Lori J Goldstein, Mauro Mansutti, Christelle Levy, et al.
Breast Cancer Research and Treatment|September 13, 2005
Clinical and radiologic assessments to predict breast cancer pathologic complete response to neoadjuvant chemotherapyAnne F Schott, Marilyn A Roubidoux, Mark A Helvie, et al.
Translational Oncology|April 29, 2014
Image registration for quantitative parametric response mapping of cancer treatment responseJennifer L Boes, Benjamin A Hoff, Nola Hylton, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|September 29, 2009
Fever and neutropenia clinical practice guidelinesAlison G Freifeld, Lindsey Robert Baden, Arthur E Brown, et al.
Pageof 7